Provided by Tiger Fintech (Singapore) Pte. Ltd.

Milestone Pharmaceuticals Inc.

1.65
-0.0200-1.20%
Post-market: 1.62-0.0288-1.75%19:59 EDT
Volume:2.02M
Turnover:3.32M
Market Cap:140.19M
PE:-2.47
High:1.71
Open:1.69
Low:1.59
Close:1.67
Loading ...

TD Cowen Sticks to Its Hold Rating for Milestone Pharmaceuticals (MIST)

TIPRANKS
·
14 Jul

Milestone prices $52.5M common shares offering at $1.50 per share

TIPRANKS
·
12 Jul

BUZZ-U.S. STOCKS ON THE MOVE-AeroVironment, Civista Bancshares, Meta

Reuters
·
12 Jul

BRIEF-Milestone Pharmaceuticals Announces Pricing Of $52.5 Million Public Offering

Reuters
·
11 Jul

Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series a Common Warrants and Series B Common Warrants

THOMSON REUTERS
·
11 Jul

Why Is Milestone Pharmaceuticals Stock (MIST) Down 30% Today?

TIPRANKS
·
11 Jul

BUZZ-U.S. STOCKS ON THE MOVE-Levi Strauss, Crypto Stocks, Delta

Reuters
·
11 Jul

Milestone Pharmaceuticals Says FDA Accepted for Review Cardamyst Nasal Spray Resubmission

MT Newswires Live
·
11 Jul

Milestone Pharmaceuticals Launches Securities Offering

MT Newswires Live
·
11 Jul

Milestone Pharmaceuticals commences underwritten public offering

TIPRANKS
·
11 Jul

BRIEF-Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™

Reuters
·
11 Jul

Milestone Pharmaceuticals Inc - Proceeds to Fund Clinical Development and Launch of Etripamil

THOMSON REUTERS
·
11 Jul

Milestone Pharmaceuticals Announces Proposed Public Offering

THOMSON REUTERS
·
11 Jul

Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the Crl for Cardamyst™ (Etripamil) Nasal Spray

THOMSON REUTERS
·
11 Jul

Milestone Pharmaceuticals Inc - Transferred Duties of Manufacturing Testing Facility to Vendors With FDA Inspection History

THOMSON REUTERS
·
11 Jul

Milestone Pharmaceuticals Inc - FDA Assigns Pdufa Action Date of December 13, 2025

THOMSON REUTERS
·
11 Jul

Milestone Pharmaceuticals Inc - Extends $75 Mln Royalty Agreement With Rtw Until 2025

THOMSON REUTERS
·
11 Jul

BRIEF-Milestone Pharmaceuticals Submits Response To The FDA’s CRL For CARDAMYST (Etripamil) Nasal Spray For PSVT Following Type A Meeting

Reuters
·
16 Jun

Milestone Pharmaceuticals Submits Response to the FDA’s Crl for Cardamyst (Etripamil) Nasal Spray for Psvt Following Type a Meeting

THOMSON REUTERS
·
16 Jun

Milestone Pharmaceuticals Inc: Believe Type a Meeting With FDA Provided Guidance to Submit Response to Crl Directly After Meeting

THOMSON REUTERS
·
16 Jun